Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d. in asthma patients: a 12-week pilot study

Journal Title: Journal of Pulmonology and Respiratory Research - Year 2017, Vol 1, Issue 1

Abstract

Two of the most recent LABA/ICS combinations for treatment of persistent asthma are Fluticasone furoate/Vilanterol 92/22 µg (Ellipta) and Beclomethasone dipropionate/Formoterol 100/6 µg (Nexthaler).

Authors and Affiliations

Claudio Terzano, Francesca Oriolo

Keywords

Related Articles

COPD and low plasma vitamin D levels: Correlation or causality?

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death and its prevalence and incidence is also related to smoking behavior [1]. COPD is still a chronic inflammatory and progressive disease caus...

Effect of diabetes mellitus on the Pulmonary Function Tests in Sudanese Diabetic Patients

Background: Diabetes mellitus is a leading cause of illness and death. Pulmonary function test PFT has assumed a key role in epidemiological studies investigating the incidence, natural history and causality of lung dise...

Successful treatment of late-onset pulmonary hypertension after atrial septal defect operation with macitentan: Our center experience

Background: Macitentan significantly improves pulmonary hemodynamics and survival in patients with primary pulmonary hypertension (PPH). Its beneficial effect, however, may be blunted due to the adverse impacts such as a...

A decade of targeted therapy for non-small cell lung cancer

Chemotherapy is one of the main treatment options for cancer. However, chemotherapeutic agents usually suffer from poor pharmaceutical properties that restrict their use. Targeted therapy drugs have been developed to spe...

Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d. in asthma patients: a 12-week pilot study

Two of the most recent LABA/ICS combinations for treatment of persistent asthma are Fluticasone furoate/Vilanterol 92/22 µg (Ellipta) and Beclomethasone dipropionate/Formoterol 100/6 µg (Nexthaler).

Download PDF file
  • EP ID EP560445
  • DOI 10.29328/journal.jprr.1001004
  • Views 42
  • Downloads 0

How To Cite

Claudio Terzano, Francesca Oriolo (2017). Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d. in asthma patients: a 12-week pilot study. Journal of Pulmonology and Respiratory Research, 1(1), 13-22. https://europub.co.uk./articles/-A-560445